On July 29, 2021, Sanofi announced its second quarter 2021 results. The pharmaceutical company reported net sales growth at constant exchange rate (CER) of 12.4%, up to €8.7 billion, driven primarily by continued strong Dupixent results and increased demand for flu vaccines. On a reported basis, sales were up by 6.5%, which factor in a negative exchange rate movement of 5.9%. The negative currency movement was attributed to weakness in the US dollar, Japanese yen, Turkish lira and Argentine pesos. The top line growth inevitably resulted in higher profitability. Sanofi reported that gross profit in the second quarter increased by 13.5% at CER and business operating income was reported 13.8% higher at CER, on a comparative basis. Click here to access the report